Latest Orphan drug Stories
Winners include Teva's Coxapone, a specialty drug for the treatment of chronic disease, and Corcepts' KORLYM, an orphan drug for a rare condition NEW YORK, May 7, 2014 /PRNewswire/
PURIXAN(TM) (mercaptopurine) Oral Suspension Finally Makes Accurate Dosing Simple for Healthcare Professionals to Achieve--Especially with Children FRANKLIN, Tenn., April 30, 2014 /PRNewswire/
LONDON, April 29, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
The company releases white paper focused on a growing trend in the industry RESEARCH TRIANGLE PARK, N.C., April 24, 2014 /PRNewswire/ -- Marken announced today the
DUBLIN, April 17, 2014 /PRNewswire/ -- Heart Metabolics Limited, a new Irish biotechnology company focused on development of drugs for cardio-metabolic diseases, has announced the completion
Symposium to Highlight How Legislation in Europe and U.S.
MADISON, Wis., April 7, 2014 /PRNewswire/ -- The European Medicines Agency (EMA) has granted Minor Use Minor Species (MUMS) designation for Nexcyon's adrenocorticotropin (ACTH), a synthetic
Cambridge Biomedical Inc. announces that their Chief Operating Officer, Dr. John Reddington, will be attending the 4th annual World Orphan Drug Congress in Washington D.C.
DUBLIN, April 1, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/5q5tcr/global_orphan) has announced the addition of the "Concise
Frost & Sullivan: Breakthrough therapies for rare diseases command premium pricing, particularly if no alternatives exist MOUNTAIN VIEW, Calif., March 25, 2014 /PRNewswire/ -- The global orphan
- A morbid dread of being buried alive. Also spelled 'taphiphobia'.